Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Managing your weight is rarely a simple journey. For years, patients and doctors have navigated complicated treatment plans. Often, these plans yielded mixed long-term results. Recently, a class of medications called GLP-1 receptor agonists completely changed the landscape of obesity…
For years, the biggest hurdle with GLP-1 medications wasn’t effectiveness. It was the needle. So Eli Lilly’s orforglipron may have just changed that entirely. The FDA approved orforglipron on April 1, 2026, for chronic weight management. Specifically, it targets adults…
Eli Lilly may be getting closer to putting a weight loss pill on pharmacy shelves. The company recently announced strong results from a large Phase 3 trial of orforglipron. It’s an experimental daily pill designed to work like injectable GLP-1…
A new pill called orforglipron helps people keep weight off after they stop using shots. Research published in Nature Medicine shows that this daily medicine works well for maintenance. It assists patients who previously used popular injectable treatments to manage…
The oral glucagon-like peptide-1 (GLP-1) weight-loss market is entering a period of rapid expansion. In view of this, GlobalData forecasts weight-loss pill revenues will rise to $34.3 billion. To be precise, this growth will disrupt traditional retail food and beverage…